Education
About Us
Working with TipRanks
Follow Us
BeiGene (ONC)
NASDAQ:ONC
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$141.31 - $287.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)528.60K
Market Cap
$29.57B
Enterprise Value$22.17B
Total Cash (Recent Filing)$13.90M
Total Debt (Recent Filing)$13.84M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 22, 2025EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding98,910,760
10 Day Avg. Volume373,527
30 Day Avg. Volume528,597
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-55.80
Forecast
1Y Price Target
$320.21Price Target Upside37.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
BeiGene News
PremiumCompany Announcements
BeiGene Reports Strong Q1 2025 Growth and Profitability
PremiumCompany Announcements
BeiGene’s Earnings Call: Record Growth & Strategic Advances
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement achieved their first quarter of GAAP profitability, showing consistent financial execution with strong sales and tight OpEx control.
Market ShareBrukinsa is now the #1 BTKi in the US and looks on pace to become #1 globally by YE25, indicating strong market performance.
Revenue GrowthBrukinsa generated $828MM in global sales, showing significant growth, with $616MM from the U.S., indicating its strong market presence.
Bears Say
Clinical Trial SetbackThe AMPLIFY trial, Phase 3 study evaluating fixed-duration treatment with acalabrutinib combined with venetoclax, failed to meet expectations.
CompetitionConcerns for future competition to Tevimbra in China from Akeso/Summit's ivonescimab, which is unlikely to have NRDL coverage until at least FY27.
---
Ownership Overview
Currently, No data available
---
ONC FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $141.31 and its highest was $287.88 in the past 12 months.
What is BeiGene’s market cap?
BeiGene’s market cap is $29.57B.
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is Aug 22, 2025 which is in 105 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on May 07, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.531 by $0.531.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is 0.19.
How many shares outstanding does BeiGene have?
BeiGene has 98,910,760 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of $0 in its last earnings report, beating expectations of -$0.531. Following the earnings report the stock price went down -3.93%.
Which hedge fund is a major shareholder of BeiGene?
Currently, no hedge funds are holding shares in ONC
---
BeiGene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$320.21 (37.87% Upside)
$320.21 (37.87% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 908.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $190.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.78%
12-Months-Change
Fundamentals
Return on Equity
-18.77%
Trailing 12-Months
Asset Growth
2.06%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
---
ONC Company Deck
---
ONC Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial and operational performance with significant revenue growth, market leadership, and pipeline advancements. Despite challenges in fixed-duration treatments and navigating a complex global environment, the company's strategic initiatives and investments are positioning it well for future growth.Read More>---
ONC Stock 12 Month Forecast
Average Price Target
$320.21
▲(37.87% Upside)
Technical Analysis
---